TandemAI to merge with Perpetual Medicines.

TandemAI, is an advanced technology company, agreed to merge with Perpetual Medicines, an integrated computational peptide therapeutics company. Financial terms were not disclosed. “The commercial and clinical successes of GLP-1, IL-23, and PCSK9 drug classes have greatly expanded the global commercial opportunity for peptide-based therapeutics. Our AI/computational platform is designed to capitalize on unexplored peptide chemical space to discover new therapeutics with novel attributes. The synergies we expect to realize through the merger with TandemAI, will greatly accelerate these efforts,” Kerry L. Blanchard, Perpetual Medicines Co-Founder, Chairman, and CEO.